Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma - Test2 - elhamkhani - TriplyDB

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

http://www.wikidata.org/entity/Q24669938

about

Cyclin-dependent kinase inhibitor therapy for hematologic malignancies A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity Characterization of cyclin E expression in multiple myeloma and its functional role in seliciclib-induced apoptotic cell death Evolving Therapies and FAK Inhibitors for the Treatment of Cancer ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia.Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.Cell cycle re-entry and mitochondrial defects in myc-mediated hypertrophic cardiomyopathy and heart failure.Endogenous Bak inhibitors Mcl-1 and Bcl-xL: differential impact on TRAIL resistance in Bax-deficient carcinoma.Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.Kinase activity profiling of pneumococcal pneumonia Antitumor activity of a novel oncrasin analogue is mediated by JNK activation and STAT3 inhibition The cyclin-dependent kinase inhibitor SCH 727965 (dinacliclib) induces the apoptosis of osteosarcoma cells Histone deacetylase 3 as a novel therapeutic target in multiple myeloma.The impact of CDK inhibition in human malignancies associated with pronounced defects in apoptosis: advantages of multi-targeting small molecules.Anti-apoptotic BFL-1 is the major effector in activation-induced human mast cell survival The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines.Analogues and derivatives of oncrasin-1, a novel inhibitor of the C-terminal domain of RNA polymerase II and their antitumor activities.Roscovitine-induced apoptosis in neutrophils and neutrophil progenitors is regulated by the Bcl-2-family members Bim, Puma, Noxa and Mcl-1 Growth factors and antiapoptotic signaling pathways in multiple myeloma.Towards targeted therapy for infant acute lymphoblastic leukaemia.BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.Model of translational cancer research in multiple myeloma.Exploiting the p53 pathway for the diagnosis and therapy of human cancer.A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models The cyclin dependent kinase inhibitor (R)-roscovitine prevents alloreactive T cell clonal expansion and protects against acute GvHD Bim upregulation by histone deacetylase inhibitors mediates interactions with the Bcl-2 antagonist ABT-737: evidence for distinct roles for Bcl-2, Bcl-xL, and Mcl-1.How to unleash mitochondrial apoptotic blockades to kill cancers?Kinase inhibitors as potential agents in the treatment of multiple myeloma.Novel therapeutic targets for multiple myeloma.Novel potent pharmacological cyclin-dependent kinase inhibitors.Cyclin dependent kinases in cancer: potential for therapeutic intervention.Perspective of cyclin-dependent kinase 9 (CDK9) as a drug target.Cyclin-dependent kinase modulators and cancer therapy.Cell cycle modulatory and apoptotic effects of plant-derived anticancer drugs in clinical use or development.Transcription inhibition as a therapeutic target for cancer Molecularly targeted therapies in multiple myeloma

P2860

Q24561485-645DA125-2E0B-4EF4-B82E-BA0A1882A33C Q27649579-07D5A1AE-4219-43B5-A490-F64210B7DDAA Q27670943-ECACBA65-EE48-4207-B218-5448C9D34977 Q27675539-71A5B418-F7CE-47CD-A350-AD14CC40C02D Q28482928-9E8CFC6F-BD7E-4FB6-BACE-D616DF26FFC3 Q28972291-73B2543F-04A1-4C4A-94C7-4C633980DD82 Q33405436-6CE75BB7-2CD1-451A-8108-BBBC054F765F Q33418705-814B36B0-719B-4B74-BADE-9F23B545CE8F Q33506647-87AA41C9-B92A-4859-9B40-5B0B6CE478F6 Q33544118-8A92D36C-4717-4751-ACF7-DA7737D33CB8 Q33702365-A2238E1B-E949-403D-8A38-4821013AA112 Q33869204-E5342092-490B-4353-9CD7-1CA7D0190FA9 Q34103117-D4B5FCC2-0FF6-4932-8A27-A19378CEB8B6 Q34178106-BFF16338-F9BD-4F45-85A0-FF3297DA20A3 Q34194704-3B1F2CB3-1831-4812-A0BB-1557700D80A3 Q34195072-68063086-BE12-4813-8A53-2E4006475A5A Q34312178-0FAC8DFB-7A94-4E2F-B9A9-164114D8DEAB Q34336372-789F1E22-B72D-4560-8850-8EA0D1CC8F7A Q34857289-76AB27AC-1869-4113-B064-F191BBE18312 Q35041268-A6FD99A7-E0AA-4EAB-A31C-D9D295BB9EB3 Q36292888-0F77381A-9C5A-47FA-B8E1-0306A158D5D4 Q36381561-6D9481B7-2550-43A7-824B-340B3334A788 Q36445905-A6ACD61B-DA23-4AC6-A579-F9F4E0681930 Q36498784-18DD2AEE-0D61-416E-8CEE-25FA6E93DDA5 Q36547790-D2196935-D57C-45D8-A29D-557A4C5E235C Q36610517-812B0F37-E72D-41E7-8255-DDD4A666DFA7 Q36709283-6F96D1EE-95B2-4478-B95D-80500C2AEF66 Q37226506-9F0CBDD8-AF07-4C85-9F7B-314FD822212D Q37331873-1AFE9B22-A359-4BD6-A23F-B5BBCF382A73 Q37451892-B1E2D591-47E8-4C2D-A750-176AA8E875C0 Q37587294-30837E40-2C31-4A7F-ACDB-5295463A611E Q37697253-DDBD28CC-BDC2-4771-B471-F9723CF19AFC Q37707383-B21B2F30-3913-4982-9D36-F3D595A9D742 Q37855812-F3F41E13-41D4-4CE1-8385-6EF895E26975 Q37987789-91746BEE-9768-4A15-B379-8B3FF4F448EF Q38008733-BE1A17F8-C1A5-406F-9BC9-095982297E09 Q38038670-DAC93E52-27A1-4526-A0BD-8B3495606F40 Q38088759-DCEA1446-750E-4654-95BE-070603BD3D31 Q38161381-FE061230-683A-4187-9BF7-895DE796EDC0 Q38211866-89B0430E-1F57-474A-99E0-6273FCFA821C

P2860

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

http://www.wikidata.org/entity/Q24669938

description

2005 nî lūn-bûn

@nan

2005 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

name

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@ast

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@en

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@nl

type

label

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@ast

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@en

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@nl

prefLabel

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@ast

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@en

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@nl

P1433

Q24669938-E5F0C675-78F5-46E6-B803-808B92DACC5F

P1476

Q24669938-7E087DC2-0299-4E60-B695-2486837CB201

P2093

Q24669938-0E476A7E-0856-433C-88A3-5AFECFB96AA7

Q24669938-11409147-D3E9-420B-9B92-8CB36187BC17

Q24669938-5FC71D5A-44A9-465F-BF91-9A6A20146AA6

Q24669938-6977730A-8106-4BF0-A8C4-475144252005

Q24669938-CD4CA4AB-DBC2-4277-B12C-719D1BE46340

Q24669938-DD3EDE69-6732-4DA6-BC92-664DF60D5358

Q24669938-E09FAFFA-2FD0-41C0-9586-1CDB7BACFE74

Q24669938-E6211A85-7014-4698-BC52-C46DF2ADE328

Q24669938-EF3B803F-1BF1-4941-BDC6-6A6550D90553

Q24669938-F9D97594-67C9-4729-8C56-CFB5D60E4A20

P2860

Q24669938-0CE139B7-B605-424E-8C86-8BB97AFFF471

Q24669938-14D406F9-F5F1-41A0-8DC7-192D0B4E9607

Q24669938-1BBE6680-33A7-4FAA-BDC3-809B4A0C3578

Q24669938-1C3E9114-C057-428F-B591-2E95F6FA5480

Q24669938-26A69F64-05AC-451D-BAEC-648EC7BD4916

Q24669938-2DE99746-FD90-4399-AD44-5EA4EF065706

Q24669938-30DE7F38-6A3A-4B28-A72A-7C643C69E1EE

Q24669938-4300E5E5-2C7C-4659-AE4C-52FBD1969607

Q24669938-48D5E0D5-8FF6-4690-A7E7-D8335683EA66

Q24669938-4A07E9BD-7DA6-4957-8BC3-CC9BB5987505

P304

Q24669938-B18EED0D-2C20-4A9B-9A80-78F8094BF40E

P31

Q24669938-F8C9C391-42FE-49E4-B17C-58DEA25A4809

P356

Q24669938-6DE5E5B2-801A-42B9-AA9B-7FD59F39C132

P407

Q24669938-72DC6B63-91F0-40A0-8B0A-F00FEAC789BA

P433

Q24669938-D31383D9-DBDE-44FE-9CBE-EE12C57D1E24

P478

Q24669938-10BCDA04-2C1A-428B-A69F-A28E949F3028

P50

Q24669938-75E57110-1704-47FD-83C1-F1FCCE636481

P577

Q24669938-1281EC89-2094-4375-BCBD-7EF9D3032D58

P5875

Q24669938-317F4CEB-C935-4243-B698-D049478EBB4A

P698

Q24669938-C83D738A-CA72-4B4E-90E0-370EB7DFCDE3

P921

Q24669938-AE7300AC-F4CD-4B2C-87B4-C8657C71DA91

P932

Q24669938-C8608653-AA77-46D6-85D2-6179C433A365

P356

BLOOD-2005-01-0320

P1433

P1476

Seliciclib (CYC202 or R-roscov ...... n of Mcl-1 in multiple myeloma

@en

P2093

Aldo Roccaro

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Hiroshi Yasui

http://www.w3.org/2001/XMLSchema#string

Kenji Ishitsuka

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Noopur Raje

http://www.w3.org/2001/XMLSchema#string

Norihiko Shiraishi

http://www.w3.org/2001/XMLSchema#string

Shaji Kumar

http://www.w3.org/2001/XMLSchema#string

Simon R Green

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Cancer statistics, 2004

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Cell cycle regulation and RNA polymerase II.

Antitumor activity of thalidomide in refractory multiple myeloma.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

NF-kappa B as a therapeutic target in multiple myeloma.

Thalidomide and immunomodulatory drugs as cancer therapy.

P304

1042-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2005-01-0320

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

106

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

P577

2005-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7910140

http://www.w3.org/2001/XMLSchema#string

P698

15827128

http://www.w3.org/2001/XMLSchema#string

P921

P932

1895150

http://www.w3.org/2001/XMLSchema#string